Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
In order for a tumour to grow and spread to other parts of the body, it needs to have a blood
supply. Certain proteins in the body, called cytokines or growth factors, have been shown to
cause the growth of new blood vessels that supply tumours and therefore help the tumour to
grow and spread. Motesanib (AMG 706) prevents these proteins from working, and may help to
prevent the growth of tumours.
In the first part of this study, we will look at the way your body absorbs this drug into
your blood, how your body changes and breaks down the drug, and then how the drug leaves your
body in your urine and faeces.
In order to provide potential treatment benefit for the subjects who participated in the
first part of the study, the second part of the study will allow subjects to continue on
motesanib (AMG 706) treatment. The estimated length of this part of the study is unknown, and
dependent on how subjects respond to motesanib (AMG 706).